No Data
Express News | [Test] Cuorips Inc 4894.t 2026 Group Net Loss 1.02 Bln Yen Vs Loss 644 Mln Yen, 2026/27 Forecast Loss 1.39 Bln Yen
Express News | [Test] Cuorips Inc 4894.t 2026 Group Operating Loss 1.08 Bln Yen Vs Loss 590 Mln Yen, 2026/27 Forecast Loss 1.43 Bln Yen
Cuorips: FY2026 March Quarter Earnings Briefing [Japanese GAAP] (Consolidated)
Nippon Paper, Nissan Chemical, Dentsu G, Duskin (15th) (1301-6045)
※The above calendar is tentative and subject to change based on corporate circumstances. --------------------------------------- May 15 (Fri) <1301> Kyokuyo <1379> Hokuto <1380> Akikawa Ranch <1384> Hokuryo <142A> Jinjib <1432> Doryoku <1435> RoboHome <1438> Gifu Garden <145A> El.
It was featured on the website of the Japan Agency for Medical Research and Development (AMED).
The research and development as well as the practical application of induced pluripotent stem cell (iPS cell) medical treatments have been featured on the website of the Japan Agency for Medical Research and Development (AMED). Please take a look.
On March 18, 2026, our CEO, Kusanagi, will appear on Nikkei CNBC.
On March 18, 2026, our CEO, Kusanagi, will appear on Nikkei CNBC. Broadcast Schedule: Wednesday, March 18, 2026, 10:15–10:30 Program Name: "Eiki Wajima's Stock Picking Tips" Broadcast Station: Nikkei CNBC (Simultaneous streaming on Nikkei CNBC online) URL: Interviewer: Economic Journalist Eiki Wajima We hope you will watch.